Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer

NCT07495124 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07495124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07495124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2026
Completion date
September 30, 2028
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma